N4 Pharma (GB:N4P) has released an update.
N4 Pharma PLC, a pharmaceutical company specializing in innovative delivery systems for cancer treatments, gene therapy, and vaccines, has announced the appointment of Gravita II LLP as its new auditor. This change comes after a confirmation from the outgoing auditor, Saffery LLP, that there are no concerns to be reported to the company’s stakeholders. N4 Pharma is focused on collaborating with partners to advance its proprietary delivery technologies, Nuvec® and Liptide®, and aims to generate revenue through upfront payments, milestones, and royalties as products reach the market.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
